

## Gralise® (gabapentin) - First-time generic

- On January 25, 2024, <u>Zydus launched AB-rated</u> generic versions of Almatica's <u>Gralise</u> (gabapentin) 300 mg and 600 mg tablets.
  - Gralise is also available as 450 mg, 750 mg and 900 mg tablets.
- Gralise is approved for the management of postherpetic neuralgia (PHN).
- Gabapentin is also generically available as a <u>capsule</u>, <u>oral solution</u>, and <u>tablet</u> (all previously as brand <u>Neurontin<sup>®</sup></u>). In addition gabapentin is available as brand <u>Horizant<sup>®</sup></u>.
  - Gabapentin capsule, oral solution, and tablet are indicated for the management of PHN in adults and adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy.
  - Horizant is indicated for the treatment of moderate-to-severe primary restless legs syndrome in adults and management of PHN in adults.
- According to IQVIA, Gralise 300 mg and 600 mg tablets had annual U.S. sales of \$85 million as of November 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.